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Anthrax toxin (AnTx) plays a key role in the pathogenesis of anthrax. AnTx is composed of three proteins: protective
antigen (PA), edema factor, and lethal factor (LF). PA is not toxic but serves to bind cells and translocate the toxic
edema factor or LF moieties to the cytosol. Recently, the low-density lipoprotein receptor–related protein LRP6 has
been reported to mediate internalization and lethality of AnTx. Based on its similarity to LRP6, we hypothesized that
LRP5 may also play a role in cellular uptake of AnTx. We assayed PA-dependent uptake of anthrax LF or a cytotoxic LF
fusion protein (FP59) in cells and mice harboring targeted deletions of Lrp5 or Lrp6. Unexpectedly, we observed that
uptake was unaltered in the presence or absence of either Lrp5 or Lrp6 expression. Moreover, we observed efficient
PA-mediated uptake into anthrax toxin receptor (ANTXR)–deficient Chinese hamster ovary cells (PR230) that had been
stably engineered to express either human ANTXR1 or human ANTXR2 in the presence or absence of siRNA specific for
LRP5 or LRP6. Our results demonstrate that neither LRP5 nor LRP6 is necessary for PA-mediated internalization or
lethality of anthrax lethal toxin.
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lethality of anthrax lethal toxin. PLoS Pathog 3(3): e27. doi:10.1371/journal.ppat.0030027
Introduction
Anthrax is caused by a large, Gram-positive bacteria called
Bacillus anthracis. Early work with animal models for anthrax
established a central role for an exotoxin (anthrax toxin
[AnTx]) in its pathogenesis [1,2]. AnTx is comprised of three
proteins: protective antigen (PA), edema factor (EF), and
lethal factor (LF). PA, by itself, is not toxic. Instead, it serves
to translocate EF or LF to the cytosol [3–6]. LF is a Zn
2þ-
metalloprotease which speciﬁcally cleaves the NH2-termini of
mitogen-activated protein kinase kinases (MKKs) 1–4, 6, and
7, but not MKK 5 [7–10], resulting in their inactivation
[7,11,12]. Combinations of PA plus EF or LF are respectively
referred to as edema toxin or lethal toxin (LeTx) [13]. In vitro,
treatment of some murine macrophage–derived cell lines
with LeTx causes abrupt cell death by lysis [14] (see Video S1).
Two cell surface receptors for PA (anthrax toxin receptor
[ANTXR] 1 and 2) have been identiﬁed [15,16]. Following
binding to ANTXR, PA is cleaved by cell surface–associated
furin, removing a 20-kDa fragment and leaving a 63-kDa
fragment attached to the receptor. This step is necessary to
reveal a binding site for EF or LF [17], as well as to remove
steric hindrances to its subsequent oligomerization into a
heptamer [6,18,19]. Following this, the toxin complex
internalizes via the endosomal pathway [14,20,21].
Using an expressed sequence tag (EST) screen to inactivate
chromosomal genes, Wei et al. [22] recently reported that
LRP6 plays an essential role in PA-dependent internalization
of anthrax LF. LRP6 and the closely related LRP5 are
grouped together as a distinct subfamily of low-density
lipoprotein (LDL) receptor–like proteins, based upon their
common distinctive extracellular structure consisting of four
repeats of a prototypic YWTD b-propeller-EGF-like domain
[23–25]. They are co-receptors for Wnt ligands, which is a
large family of secreted glycoproteins that initiate signaling
by binding to members of the Frizzled family of seven
transmembrane receptors [26]. Loss-of-function mutations in
mice have shown the importance of Wnt molecules in the
development of numerous tissues and organs [27]. Lrp6-
deﬁcient mice display phenotypes similar to, but not as severe
as, those seen in several Wnt gene knockouts, and die between
embryonic day 14.5 and birth [28]. The Drosophila homolog of
LRP5 and LRP6, arrow, is required for Wnt signaling in the ﬂy,
and loss of arrow phenocopies loss of wingless (wg) [29]. Mice
homozygous for an allele of Lrp5 encoding a truncated
version of the protein recapitulate features of the autosomal
recessive human disorder osteoporosis pseudoglioma syn-
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markedly decreased bone mineral density and persistence of
the embryonic hyaloid vascular system [32–35]. Mutations
that inactivate the LRP5 gene in humans cause OPPG [36].
Further conﬁrming the importance of LRP5 in accruing
normal bone mass, families with an autosomal dominant
syndrome characterized by extremely high bone mineral
density have gain-of-function point mutations in LRP5 [37–
40]. In addition, mice engineered to express a point mutant of
Lrp5 associated with high bone mass in humans also develop
high bone mass [41].
Based on the related structure and function of LRP6 and
LRP5 in Wnt signaling, we reasoned that LRP5 might also
play a role in PA-mediated toxicity. To test this, we assayed
PA-mediated uptake of LF or FP59, a chimeric toxin
consisting of the amino-terminus of LF fused with Pseudomo-
nas exotoxin A, in vitro and in vivo using cells and mice
harboring targeted deletions of Lrp5. In both cases, PA
mediated efﬁcient delivery of toxin. Unexpectedly, similar
results were obtained for mice harboring targeted deletions
of Lrp6. Contrary to a previous report, our results demon-
strate that neither LRP5 nor LRP6 is necessary for PA-
mediated internalization or lethality of anthrax LeTx.
Results
Neither Loss of Lrp5 Expression nor Heterozygous
Expression of Lrp6 Impairs LeTx Lethality In Vivo
Wei et al. [22] reported that a polyclonal antibody raised
against LRP6 could protect cells from killing by LeTx. Based
on this result, the authors suggested that the immunological
targeting of LRP6 may prove useful in protecting against the
effects of accumulated toxin during the late stages of anthrax
disease when antibacterial methods normally are no longer of
therapeutic value. To test this hypothesis, we challenged mice
having targeted deletions of Lrp5 [42] or Lrp6 [28] with daily
intravenous injections of anthrax LeTx (50 ug of PA and 10
ug of LF). Previous work in our lab with athymic nude mice
on a BALB/cJ background has shown that this dose of LeTx is
sufﬁcient to cause hypotensive shock leading to death within
6 d (unpublished data). Lrp6
 /  mice were not used in this
experiment since they do not survive to birth [28]. Regardless
of the status of Lrp5 or Lrp6 expression, mice injected with
LeTx died within 6 d of the start of treatment (Figure 1).
These results indicate that neither loss of Lrp5 expression nor
heterozygous expression of Lrp6 impairs LeTx lethality.
Neither Lrp5 nor Lrp6 Is Essential for PA-Mediated Uptake
of FP59 or LF In Vitro
Wei et al. [22] observed that antisense expression of an EST
corresponding to an intronic sequence between exons 21 and
22 of the LRP6 gene could 1) reduce expression of LRP6, and
2) protect M2182 prostate carcinoma cells from PA-mediated
uptake of FP59, a cytotoxic fusion protein consisting of the
N-terminus of LF genetically fused with the ADP-ribosylating
domain of Pseudomonas exotoxin A [43]. These observations
formed the basis for their conclusion that LRP6 was essential
for PA-dependent uptake into cells. To test whether Lrp5 was
essential for PA-mediated internalization, we isolated murine
embryonic ﬁbroblasts (MEFs) from Lrp5
þ/þ parental, Lrp5
þ/ 
heterozygous, and Lrp5
 /  nullizygous mice, and treated them
with PA plus FP59. Lrp5
þ/þparental, Lrp5
þ/ heterozygous, and
Lrp5
 /  nullizygous MEFs demonstrated equal sensitivity to
treatment with a constant amount of PA plus varying
concentrations of FP59 (Figure 2A), or with a varying amount
of PA plus constant concentrations of FP59 (Figure 2B).
These results indicate that loss of Lrp5 expression alters
neither MEF sensitivity to FP59 nor the ability of PA to
translocate FP59 into cells. As an independent measure of
PA-mediated entry, MEFs were treated with PA plus LF, and
lysates were immunoblotted for N-terminal proteolysis of
mitogen activated protein kinase/extracellular signal-regu-
lated kinase kinase (MEK) 1. Lrp5
þ/þ parental, Lrp5
þ/ 
heterozygous, and Lrp5
 /  nullizygous MEFs demonstrated
equal cleavage of MEK1 following treatment with PA plus LF
(Figure 2C). These observations demonstrate that the loss of
expression of LRP5 is not sufﬁcient to prevent PA-mediated
uptake of FP59 or LF. Similar tests were performed with
MEFs from Lrp6
þ/þparental, Lrp6
þ/ heterozygous, and Lrp6
 / 
nullizygous mice. Each of these MEFs demonstrated equal
sensitivity to treatment with combinations of PA plus FP59
(Figure 2A and 2B). Again, as an independent measure of PA-
mediated entry, MEFs were treated with PA plus LF, and
lysates were immunoblotted for N-terminal proteolysis of
MEK1. Lrp6
þ/þ parental, Lrp6
þ/  heterozygous, and Lrp6
 / 
nullizygous MEFs demonstrated equal MEK1 cleavage follow-
ing treatment with PA plus LF (Figure 2C). These observa-
tions indicate that the loss of expression of Lrp6 is not
sufﬁcient to prevent PA-mediated uptake of FP59 or LF.
Collectively, these results demonstrate that neither Lrp5 nor
Lrp6 is essential for PA-mediated uptake of FP59 or LF.
Neither Lrp5 nor Lrp6 Functions in a Receptor-Specific
Fashion
The results discussed above indicate that PA can mediate
entry of toxin into cells in the absence of either Lrp5 or Lrp6
and are at odds with a recent study in which an essential role
for LRP6 in internalization and lethality of AnTx was
reported [22]. In that study, the authors showed that LRP6-
speciﬁc small interfering RNA (siRNA) and polyclonal anti-
bodies raised against peptides corresponding to the extrac-
ellular domain of LRP6 could protect M2182 human prostate
carcinoma cells and RAW264.7 murine macrophages from
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Author Summary
The effects of many pathogenic bacteria are caused by the toxins
they release. The toxin released by bacteria that cause anthrax is
particularly fascinating since it is made of three different proteins:
edema factor, lethal factor, and protective antigen (PA). On their
own, each of these proteins is harmless, but when combined, they
are deadly. This is because edema factor and lethal factor can exert
their poisonous effects only after they have been moved into cells
by PA. Determining exactly how PA does this is seen as a critical step
in developing medicines that will fight anthrax. That is why a recent
report suggesting that LRP6, an outer cell protein, was needed for
PA to move the other toxin proteins into cells, was greeted with
such interest. However, we now show that mice or cells lacking
LRP6, or a related protein called LRP5, are still susceptible to anthrax
toxin. The discovery that PA can move lethal factor and edema
factor into cells without the help of LRP6 presents a significant
challenge to the previously published model. These findings will
help focus the efforts of scientists working on new ways to treat
anthrax.the lethal effects of FP59 or anthrax LeTx. One possible
explanation for this discrepancy is that the different cell
types used in these studies may differentially express
ANTXR1 or ANTXR2 and that LRP6 acts in a receptor-
speciﬁc fashion.
We used reverse-transcription PCR (RT-PCR) to compare
the expresssion of ANTXR 1 and 2 in both the MEFs that we
used, M2182 cells, and RAW264.7 cells. Interestingly, whereas
MEFs uniformly expressed both ANTXR1a n dANTXR2,
M2182 expressed ANTXR1 and undetectable levels of
ANTXR2, and RAW264.7 cells expressed ANTXR2a n d
undetectable levels of ANTXR1 (Figure 3A). Similar results
have been previously obtained for ANTXR expression in
RAW264.7 cells [44]. This indicates that the cell lines used in
the previous study and the MEF cells used in this study do
indeed differentially express ANTXR.
Based on these results, we speculated that PA-mediated
internalization via LRP6 may work preferentially through
either ANTXR1 or ANTXR2. Accordingly, we predicted that
loss of Lrp5 or Lrp6 expression would disrupt PA-mediated
uptake via one ANTXR but not the other. To test this
hypothesis, we assayed the effects of siRNA inhibition of Lrp5
and Lrp6 expression upon PA-dependent uptake of FP59 in
ANTXR-deﬁcient PR230–Chinese hamster ovary (CHO) cells
that were engineered to stably express either human ANTXR1
(T-CHO) or human ANTXR2 (C-CHO). Using RT-PCR, we
conﬁrmed previous observations [45,46] that these cell lines
express neither ANTXR1a n dANTXR2, ANTXR1, nor
ANTXR2, respectively (Figure 3A). By immunoblotting for
the NH2-terminus of MEK1, we also conﬁrmed that T-CHO
and C-CHO, but not PR230-CHO, were capable of internal-
izing LF in a PA-dependent fashion (unpublished data; Figure
4B). To knock down Lrp expression in these cells, we tested
three siRNA for Lrp5 and three siRNA for Lrp6. Although
these siRNAs were designed to inhibit mouse mRNA, we
expect that hamster sequences will be highly homologous, if
not identical; the hamster mRNA sequence obtained for
regions of Lrp5 and Lrp6 that we used to design our PCR
primers were 91%–95% identical to those published for mice
(unpublished data). Using real-time PCR, we established that
Lrp5-siRNA2 and Lrp5-siRNA3 were most effective in
reducing Lrp5 expression, and Lrp6-siRNA1 was most
effective for reducing Lrp6 expression (Figure 3B). Notably,
the Lrp6-siRNA1 caused a similar level of mRNA inhibition as
the siRNA used by Wei et al. [22]. Immunoblots with
antibodies speciﬁc for Lrp5 showed that its levels were
reduced in response to either siRNA-2 or siRNA-3, though
the levels of protein did not strictly correlate with the level of
mRNA expression (Figure 3C). Antibodies against Lrp6 did
not work well in immunoblots (unpublished data), so we
indirectly assayed Lrp6 protein expression by assaying the
ability of siRNA-treated cells to bind the Lrp6 ligand DKK-1.
Whereas treatment of PR230-CHO cells with Lrp6 siRNA-1
caused a clear reduction in DKK-1 binding, treatment with
control siRNA did not cause any discernable loss of DKK-1
binding (Figure 3D). These results indicate that siRNA
directed against either Lrp5 or Lrp6 can selectively reduce
targeted mRNA and protein expression levels.
Regardless of the level of knockdown achieved, none of the
siRNA had a demonstrable effect on PA-mediated uptake of
FP59 (Figure 4A). In addition, none of the siRNA had any
noticeable effect upon PA-mediated uptake of LF, as judged
by immunoblotting for NH2-terminal epitopes of MEK1
(Figure 4B). These data indicate that PA-mediated internal-
ization via either LRP5 or LRP6 does not work preferentially
through either ANTXR1 or ANTXR2.
Finally, we examined the possibility that Lrp5 or Lrp6 are
functionally redundant and that PA-mediated internalization
requires expression of either Lrp5 or Lrp6. MEFs isolated
from Lrp6 knockout mice were treated with Lrp5-speciﬁc
siRNA and assayed for sensitivity to PA plus FP59 or LF.
Using real–time PCR, we established that Lrp5-siRNA1, Lrp5-
siRNA2, and Lrp5-siRNA3 were similarly effective in reducing
Lrp5 expression by approximately 66%–80% (Figure 5A).
Despite this, reduced expression of Lrp5 in this Lrp6 null
background had no effect upon sensitivity of MEFs to PA plus
FP59 (Figure 5B) or upon LF cleavage of MEK1 (Figure 5C).
Similar results were obtained when we treated Lrp5 null MEFs
with siRNA speciﬁc for Lrp6, or when we treated T-CHO cells
with a combination of Lrp5-siRNA2 and Lrp6-siRNA1
(unpublished data). These results indicate that PA-mediated
internalization by MEFs or CHO cells proceeds independ-
ently of the expression of Lrp5 and Lrp6.
Discussion
Of the three AnTx proteins, PA is the central receptor-
binding component, or B moiety, that delivers the catalytic
effector molecules, LF or EF, to the cytosol [21]. Before it can
do this, PA must bind a cell surface receptor. Cell surface
Figure 1. LeTx Challenge of LRP5- and LRP6-Deficient Mice
To assess the effects of LRP5 or LRP6 deficiency upon LeTx sensitivity in
vivo, LRP5
þ/þ parental (n¼9), LRP5
þ/  heterozygous (n¼4), and LRP5
 / 
nullizygous (n ¼ 4) mice, as well as LRP6
þ/þ parental (n ¼ 6) and LRP6
þ/ 
heterozygous (n¼8) mice, were injected daily via the tail vein with 50 ll
of neutral buffered saline containing PA (50 ug) and lethal factor (10 ug).
The percentage of mice surviving treatment is plotted versus the
numbers of days after the mice first received an injection of LeTx. ko/ko,
homozygous for knockout allele; ko/þ, heterozygous for the knockout
allele and the wild-type allele; þ/þ, homozygous for the wild-type allele.
doi:10.1371/journal.ppat.0030027.g001
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ﬁrst receptor identiﬁed (ANTXR1) was a splice variant (sv2)
of TEM8, a protein of unknown function that is up-regulated
in colorectal cancer endothelium [47]. Young and colleagues
now report that of three TEM8 splice variants tested, two (sv1
and sv2) function as an ANTXR, while the third (sv3) does not
[16]. sv1 and sv2 differ only in the length of their cytoplasmic
tails, but analysis of ANTXR1 deletion mutants indicates that
this tail is dispensable for receptor function [45]. More
recently, Scobie et al. [16] identiﬁed a second receptor
(ANTXR2) encoded by capillary morphogenesis gene 2
(CMG2). As this name suggests, ANTXR2 is a protein which
is up-regulated during endothelial cell morphogenesis [48].
Both ANTXR1 and ANTXR2 are ubiquitously expressed,
making it likely that the participation of each is relevant to
the pathology of anthrax.
Wei et al. [22] made a well-reasoned argument that LRP6 is
essential for PA-dependent internalization of AnTx. Based on
their initial ﬁndings, we further tested the requirement for
not only Lrp6, but also Lrp5, in PA-dependent uptake of
FP59 or LF. However, our results have directed us to the
opinion that neither Lrp5 nor Lrp6 is essential for PA-
dependent uptake into cells. This position is supported by
three independent and compelling lines of evidence. First,
mice with targeted deletions of Lrp5 or Lrp6 are as sensitive as
wild-type mice to intravenous injections of anthrax LeTx.
Second, wild-type MEFs and MEFs lacking expression of Lrp5
or Lrp6 are equally capable of internalizing either FP59 or LF
in a PA-dependent fashion. Finally, knockdown of Lrp5 or
Lrp6 with siRNA neither alters the sensitivity of CHO cells
expressing ANTXR1 or ANTXR2 to FP59 nor prevents NH2-
terminal proteolysis of MEK1 by LF. Thus, the available
evidence does not support the hypothesis that either LRP5 or
LRP6 plays an essential role in PA-mediated uptake.
We propose several alternative explanations for the
discrepancy between our results and those of Wei et al. [22].
First, LRP6 may function in a species-speciﬁc fashion.
Though Wei et al. [22] presented data from both human
M2182 prostate carcinoma cells and mouse RAW264.7
macrophages, the protection conferred by siRNA in the
latter was only modest (an approximately 2- to 3-fold
increase in the IC50) when compared to that in the former
(.100-fold increase in the IC50). Perhaps RAW264.7 cells, as
well as MEF and CHO cells, express a splice variant of Lrp6
that is resistant to siRNA treatment? This seems unlikely
given the highly conserved nature of LRP6; LRP6 and Lrp6
share 97% protein sequence identity. Moreover, though the
Ensembl browser (version 41, October 2006; http://www.
Figure 2. In Vitro Treatment of Embryonic Fibroblasts from LRP5- and LRP6-Deficient Mice with PA Plus FP59 or LF
(A) To assess the effects of LRP5 or LRP6 deficiency upon LeTx-sensitivity in vitro, embryonic fibroblasts from LRP5 and LRP6 parental (þ/þ),
heterozygous (ko/þ), and nullizygous (ko/ko) mice were treated with PA (1 ug/ml) and FP59 (20 pg/ml–2 ug/ml). Cell viability (oordinate) at the end of
24 h of incubation is plotted versus the concentration of FP59 (abcissa). Error bars indicate standard deviation between three replicates in a single
experiment.
(B) Alternatively, embryonic fibroblasts from the same mice were treated with FP59 (1 ng/ml) and PA (1 pg/ml–10 ug/ml). Cell viability (oordinate) at the
end of 24 h of incubation is plotted versus the concentration of PA (abcissa). Error bars indicate standard deviation between three replicates in a single
experiment. This plot is representative of three independent experiments.
(C) As an independent indicator of PA entry into embryonic fibroblasts derived from mice with targeted deletions of LRP5 (upper panel) and LRP6
(lower panel), cleavage of MEK1 was assessed by immunoblotting with antibodies that are specific for the NH2-terminus of MEK1. UT, untreated.
doi:10.1371/journal.ppat.0030027.g002
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but not mouse Lrp5 containing an additional exon (2 base
pair [bp]) between exons 13 and 14, splice variants of Lrp6
have been not been characterized or predicted based on
human or mouse genomic sequence. Alternatively, perhaps
human ANTXRs are uniquely dependent upon LRP6
function. However, the CHO cells we used in this study
expressed only human ANTXR1 or ANTXR2. Since these
cells were equally sensitive to AnTx in the presence or
absence of siRNA speciﬁc for Lrp5 or Lrp6, this indicates
that 1) human ANTXR can bind and internalize AnTx in the
absence of (human) LRP5 or LRP6, and 2) human ANTXRs
do not have a general requirement for (murine) Lrp5 or Lrp6
in their function.
Second, LRP6 may function in a cell-speciﬁc manner. We
cannot exclude this possibility. However, Lrp6 function is
compromised even in heterozygous null mice since hetero-
zygous expression genetically enhances a Wnt mutant
phenotype [28]. Therefore, we argue that if LRP6 does
function in a cell-speciﬁc manner, it is unlikely that sensitive
cell types will play a signiﬁcant role in the pathology of
anthrax LeTx since heterozygous knockout mice are as
sensitive to LeTx as their wild-type counterparts are. Thus,
targeting of LRP6 will not likely prove useful in protecting
Figure 3. ANTXR Expression and siRNA Knockdown of LRP5 and LRP6
Reverse-transcription PCR was used to assess ANTXR expression in (A) M2182 prostate carcinoma, RAW264.7 macrophage, MEFs, and ANTXR-deficient
PR230-CHO cells that were engineered to stably express either ANTXR1 (T-CHO) or ANTXR2 (C-CHO). PCR amplification of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) is included as an mRNA control.
(B) The efficacy with which LRP5- and LRP6-specific siRNA knocked down target gene expression was measured by real-time PCR. Results are presented
as an average of three independent samples, each of which was run in duplicate. The error bars indicate the standard deviation about the mean.
(C) The effect of Lrp5-specific siRNA and control siRNA (siRNAc) upon protein levels was assessed by immunoblotting with an antibody specific to Lrp5.
Levels of a-tubulin are shown as a control for protein levels. Un., untreated.
(D) The effect of Lrp6-specific siRNA and control siRNA upon Lrp6 protein levels was assessed by DKK-1 binding assays. Nomarski and fluorescence
(FITC) images of cells are shown.
doi:10.1371/journal.ppat.0030027.g003
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of anthrax disease when antibacterial methods normally are
no longer of therapeutic value.
Third, LRP6 may function in a receptor-speciﬁc fashion. In
support of this, our PCR analysis of the MEFs used in our
study and the M2182 and RAW264.7 cells used by Wei et al.
[22] indicate these cell types differentially express ANTXR1
and ANTXR2. Despite this, knockdown of either Lrp5 or Lrp6
by siRNA failed to protect CHO cells expressing one or the
other receptor from PA-mediated entry of FP59 or LF. These
results are inconsistent with the hypothesis that LRP5 or
LRP6 functions in a receptor-speciﬁc fashion.
Fourth, it is possible that LRP5 and LRP6 are functionally
redundant with regard to PA-mediated uptake. However, we
observed that mouse and hamster cells deﬁcient for both Lrp5
and Lrp6 expression are as sensitive to PA-mediated uptake as
are control cells expressing both Lrp5 and Lrp6. Further, since
real-time PCR analysis of CHO cells (Figure 3) and M2182
cells (unpublished data) indicates that both cell types express
Lrp5 and Lrp6, the insensitivity of M2182 cells to PA-mediated
toxicity following Lrp6 knockdown is not likely explained by a
deﬁciency in Lrp5 expression. Finally, though the organiza-
tion of the extracellular domains of LRP5 and LRP6 are
similar to each other, they are markedly different from that
of other LDL receptors [49]. So while we cannot exclude the
possibility that LRP6 is functionally redundant with another
LDL receptor, this possibility is remote.
Finally, the antisense screen used by Wei et al. [22]
identiﬁed a human EST (image clone 285207) corresponding
to an intronic region between exons 21 and 22 of Lrp6.
Although the clone harboring this EST showed decreased
levels of Lrp6 protein, the lack of a direct relationship
between the EST and its apparent target Lrp6 mRNA raises
concerns regarding its speciﬁcity. Indeed, Wei and colleagues
also reported that the same EST matches a sequence of the
non-coding strand of an intron of a Bcl-2-like gene (Bcl2L14).
In contrast, for the Lrp5 and Lrp6 knockout mice used in this
study, we can be reasonably assured that only Lrp5 or Lrp6 are
targeted for inactivation, based on the original Southern
blotting of mouse embryonic stem cell (ES) clones. Moreover,
we may be reasonably assured that functional Lrp5 or Lrp6 is
not expressed in these mice or cells derived from these mice.
Figure 4. The Effect of LRP5 or LRP6 Knockdown upon PA-Dependent Uptake of FP59 and Anthrax LF
(A) The effect of Lrp5 or Lrp6 knockdown on cell sensitivity to PA plus FP59 (1 ng/ml) was assessed in ANTXR-deficient PR230-CHO cells that were
engineered to stably express either ANTXR1 (T-CHO) or ANTXR2 (C-CHO) using toxicity assays as described in Materials and Methods. Cell viability
(oordinate) at the end of 24 h of incubation is plotted versus the concentration of PA (abcissa). Representative data from one of three experiments is
presented. Error bars indicate standard deviation between quadruplicate samples, which were run pairwise on two separate plates.
(B) As an independent indicator of PA-mediated entry into the siRNA-treated CHO cells, cleavage of MEK1 following treatment with medium alone (UT),
LF alone, or lethal toxin (LT) was assessed by immunoblotting (IB) with antibodies that are specific for the NH2-terminus of MEK1. Only representative
data for negative control siRNA (med GC and lo GC siRNA), Lrp5 siRNA2, and Lrp6 siRNA1 are shown, though identical results were obtained for Lrp5
siRNA 1 and 3 as well as Lrp6 siRNA 2 and 3. Immunoblots with an antibody against the carboxy-terminus of MEK1 (MEK1-COOH) are shown as a control
for loading and protein degradation.
doi:10.1371/journal.ppat.0030027.g004
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signal peptide ATG, was replaced with an IRES-b-galactosi-
dase reporter and MC1-neomycin phosphotransferase selec-
tion cassette. Thus, despite the fact that Lrp5
 /  mice are
viable, functional LRP5 cannot be expressed. To generate
Lrp6 null mice, a large insertion containing the splice
acceptor of the mouse engrailed 2 gene, the transmembrane
domain of rat CD4, and the b-galactosidase-neo reporter was
inserted between exons 5 and 6. This insertion is therefore
expected to generate a fusion construct encoding the ﬁrst 457
of 1,370 extracellular domain amino acids of Lrp6, corre-
sponding to the ﬁrst YWTD b-propeller domain and an
epidermal growth factor–like repeat of the extracellular
domain. Signiﬁcantly, this protein lacks the intracellular
domain that Wei et al. [22] determined was essential for Lrp6
function in AnTx uptake.
In conclusion, using three independent approaches, we
have failed to ﬁnd evidence to support the hypothesis that
either LRP5 or LRP6 plays an essential role in PA-mediated
uptake. The more likely explanations for the discrepancies
between these reports is that either the EST identiﬁed by Wei
et al. [22] is not speciﬁc for LRP6, or the role of LRP6 in PA-
mediated uptake is cell-type speciﬁc. However, our results
should not be interpreted as an indication that an association
of ANTXR with PA is sufﬁcient for cellular internalization.
Indirect evidence suggests that other membrane-associated
proteins may also play a role in AnTx uptake. By chemically
cross-linking associated surface proteins, Escuyer and Collier
[50] estimated the molecular weight of PA complexed with its
receptor at approximately 170 kDa. Since the molecular
weights of activated PA, ANTXR1 sv1, ANTXR1 sv2, and
ANTXR2 are 63 kDa, 63 kDa, 41 kDa, and 43 kDa,
respectively, this indicates that either PA does not bind
ANTXR in a 1:1 ratio, or other as yet unidentiﬁed proteins
are present in this complex.
Materials and Methods
Lrp5- and Lrp6-deﬁcient mice. Lrp5-deﬁcient mice were generated
as described in [42]. Lrp6-deﬁcient mice (a gift of W. Skarnes) have
been described previously [28]. The knockout mice in this report are
maintained on a C57BL background. The genotypes of all mice used
in this study were conﬁrmed by PCR analysis of genomic DNA. All
experiments were performed in compliance with the guiding
principles of the Guide for the Care and Use of Animals by the National
Academy of Sciences Institute of Laboratory Animal Resources
Commission on Life Sciences. In addition, all procedures were
approved before use by the Institutional Animal Care and Use
Committee of the Van Andel Research Institute.
Protein expression and puriﬁcation. PA and LF were expressed in
Bacillus anthracis (BH445) and puriﬁed essentially as described by Park
and Leppla [51]. The concentration of each protein was estimated
using the bicinchoninic acid method [52] and by densitometric
analyses of Coomassie Blue-stained polyacrylamide gels.
In vivo toxicity assays. To assess the requirement for Lrp5 and
Lrp6 in response to LeTx in vivo, 6- to 20-wk-old (male) wild-type,
heterozygous, and knockout Lrp5 and Lrp6 mice were injected daily
via the tail vein with 50 ll of Hank’s buffered salt solution containing
PA (50 ug) and LF (10 ug). The animals were weighed daily and
monitored for signs of stress or discomfort.
Cell culture and reagents. J774A.1 cells (obtained from the
American Type Culture Collection, http://www.atcc.org) as well as
MEFs obtained from wild-type, heterozygous, and knockout Lrp5 and
Lrp6 mice were cultured in Dulbecco’s Modiﬁed Eagle Medium
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. M2182 cells were cultured in RPMI1640 supplemented
as described previously [53]. All cell lines were maintained at 37 8Ci n
a humidiﬁed 5% CO2 incubator. A spontaneous ANTXR-deﬁcient
CHO cell mutant (PR230-CHO) as well as PR230-CHO stably
transfected with human ANTXR1 (T-CHO) or human ANTXR2 (C-
CHO) expression vectors [45] were cultured in Ham’s F-12 medium
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin.
Cytotoxicity assays. Cells were grown in 96-well plates to 70%
conﬂuence. Cells were treated with culture medium containing PA
plus FP59 at the concentrations indicated and incubated 20 h at 37
8C. At the end of the experiment, cell viability was determined using
Figure 5. The Effect of Lrp5 Knockdown upon PA-Dependent Uptake of
FP59 and Anthrax LF in Lrp6
 /  MEFs
(A) The efficacy with which LRP5-specific siRNA knocked down target
gene expression was measured by qPCR. Results are presented as an
average of two independent samples, each of which was run in
duplicate. The error bars indicate the standard deviation.
(B) The effect of Lrp5 knockdown on cell sensitivity to PA plus FP59 (1
ng/ml) was assessed in Lrp6
 / MEFs using toxicity assays as described in
Materials and Methods. Cell viability (oordinate) at the end of 24 h of
incubation is plotted versus the concentration of PA (abcissa). Error bars
indicate standard deviation between two independent experiments,
each of which was run in quadruplicate.
(C) As an independent indicator of PA-mediated entry into the siRNA-
treated CHO cells, cleavage of MEK1 was assessed by immunoblotting
with antibodies that are specific for the NH2-terminus of MEK1. Only
representative data for negative control siRNA (med GC) and LRP5
siRNA2 are shown, though identical results were obtained for LRP5 siRNA
1 and 3. An immunoblot with an antibody against the carboxy-terminus
of MEK1 (MEK1-COOH) is shown as a control for loading and protein
degradation.
doi:10.1371/journal.ppat.0030027.g005
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(Promega, http://www.promega.com) according to the manufacturer’s
instructions.
MEK cleavage assays. To assay MEK1 cleavage, we made lysates of
murine cells which had been incubated for 4 h with 0.1 lg/ml PA and
0.01 lg/ml LF. Lysates were separated by denaturing SDS-PAGE and
immunoblotted with antibodies raised against the NH2-terminus (07–
641, 1:1000; Upstate Biotechnology, http://www.upstate.com) or the
COOH-terminus (sc-219, 1:1000; Santa Cruz Biotechnology, http://
www.scbt.com) of MEK1. Immunoblots were stripped and re-probed
for a-tubulin (T9026, 1:1000; Sigma, http://www.sigmaaldrich.com) for
a loading control.
Genotypic analysis of embryonic ﬁbroblasts. DNA was prepared
from embryonic ﬁbroblasts using an AutoGenprep 960 automated
DNA isolation system (AutoGen, http://www.autogen.com). The
sequences of the PCR primers used in this study are listed in Table
S1. PCR of the Lrp5 alleles was carried out in 25 ll of total volume
containing 2.5 llo f1 0 3 PCR buffer (Invitrogen, http://www.
invitrogen.com), 2.0 ll of DMSO, 1.0 ll of 50 mM MgCl2, 0.625 mM
of each nucleotide, 1 U of Taq polymerase (Invitrogen), a 6.25-lg/ml
concentration of primers LRP5 F or Neo F1, and a 12.5-lg/ml
concentration of primer LRP5 39-targeted (common primer) to detect
a 430-bp fragment of the wild-type allele and/or a 1,000-bp fragment
of the mutant allele. Samples were ampliﬁed for 34 cycles (94 8C for 1
min, 57.8 8C for 1 min, and 72 8C for 1 min). PCR of the wild-type Lrp6
allele was carried out as above except with no DMSO and using the
LRP6 7757-S primer and the LRP6 8085-AS primer (to detect a 325-
bp fragment). Samples were ampliﬁed for 30 cycles (94 8C for 45 s, 56.5
8C for 45 s, and 72 8C for 1 min). PCR of the mutant LRP6 allele was
carried out as above in 20 ll total volume and no DMSO using the
LRP6 7757-S primer and the pGT1.8TM-1388 AS primer (to detect a
586-bp fragment). Samples were ampliﬁed for 30 cycles (94 8C for 45 s,
56 8C for 45 s, and 72 8C for 1 min). PCR products were visualized by
ethidium bromide staining in 1.0% agarose gels.
PCR analysis of ANTXR and Lrp 5/6 expression. RNA was isolated
using the TRIzol (Invitrogen) method. Brieﬂy, cells were lysed in 10 ml
TRIzol and RNA was extracted with chloroform using a 15-ml phase-
lock tube (Eppendorf, http://www.eppendorf.com). RNA was precipi-
tated with isopropyl alcohol, washed in 75% ethanol, and pellets were
air dried. Pellets were re-suspended in nuclease-free water. Reverse-
transcription PCR of ANTXR1 was carried out in 50 ll total volume
containing 5 llo f1 0 3 PCR buffer (Invitrogen), 1.5 llo f5 0m M
MgCl2, 0.2 mM of each nucleotide, 0.4 ll of Taq Polymerase, and 0.20-
lM concentration of primers. To detect murine ANTXR1, we used the
primers mANTXR1 F and mANTXR1 R (to detect a 258-bp fragment).
To detect human ANTXR1, we used the primers hANTXR1 F and
hANTXR1 R to detect a 256-bp fragment. Samples were ampliﬁed for
36 cycles (94 8C for 45 s, 55 8C for 30 s, and 72 8C for 1.5 min). RT-PCR
of ANTXR2 was carried out as described above except that the
following primers were used: mouse mANTXR2 F and mANTXR2 R
to detect a 364-bp fragment, and human hANTXR2 F and hANTXR2
R to detect a 344-bp fragment. PCR products were visualized by SYBR
Safe DNA gel stain (Invitrogen) in 1.0% agarose gels. The identity of
the PCR products was conﬁrmed by DNA sequencing.
RT-PCR of Lrp5 and Lrp6 from CHO cells was carried out
essentially as described. The following primers were used: Lrp5 bp336
F and Lrp5 bp895 R (to detect a 559-bp fragment), Lrp5 bp2230 F and
Lrp5 bp2699 R (to detect a 469-bp fragment), and ham Lrp6 F and
ham Lrp6 R. Samples were ampliﬁed for 36 cycles (94 8C for 45 s, 60
8C (or 55 8C for Lrp6) for 30 s, and 68 8C for 3 min). PCR products
were visualized by SYBR Safe DNA gel stain (Invitrogen) in 1.0%
agarose gels. The identity of the PCR products was conﬁrmed by DNA
sequencing. These partial sequences were used later to generate
primers for real-time PCR.
Inhibition of Lrp5 and Lrp6 expression. To inhibit Lrp5 and Lrp6
gene expression in CHO cells and MEFs, we utilized Stealth RNAi to
knock down mouse Lrp5 and Lrp6 (Invitrogen). Stealth RNAi low GC
and medium GC duplexes were used as negative controls for Lrp6 and
Lrp5, respectively. Cells were transfected at 30% conﬂuence using
Lipofectamine 2000 according to the manufacturer’s protocol
(Invitrogen) with a ﬁnal concentration of 40 nM siRNA. After 48 h
incubation, cells were treated with culture medium containing PA
plus FP59 at the concentrations indicated for 3 h, after which the
toxin-containing medium was removed, fresh medium added, and
cells were incubated for an additional 16 h at 37 8C. At the end of the
experiment, cell viability was determined using the CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay as described
above. Additionally, to analyze the effect of siRNA treatment on
the function of LeTx, treated cells were subjected to LeTx (0.1 lg/ml
PA and 0.01 lg/ml LF) or LF alone (0.01 lg/ml LF) for 4 h, after which
cells were either collected for analysis of MEK cleavage or for
veriﬁcation of mRNA knockdown.
Real-time PCR of Lrp5 and Lrp6. To analyze Lrp5 or Lrp6 mRNA
levels after siRNA treatment, quantitative real-time PCR was
performed using TaqMan One-Step RT-PCR Master Mix (Applied
Biosystems, http://www.appliedbiosystems.com) and detected using
the Applied Biosystems 7300 Real-Time PCR System. Analysis of the
level of 18S ribosomal RNA (18S rRNA) in each sample was
performed as an internal loading control. Primers and probes were
designed based on partial mRNA sequence for hamster Lrp5 and
Lrp6 using Primer Express software (Applied Biosystems). Real-time
RT-PCR was carried out under the following conditions: 23 Master
Mix without UNG (13 ﬁnal concentration), 403 MultiScribe and
RNase Inhibitor Mix (0.25 U/uL and 0.4 U/uL, respectively, ﬁnal
concentration), 200 nM (Lrp5/6) or 50 nM (18S rRNA) forward (ham
F) and reverse (ham R) primers, 100 nM (Lrp5/6) or 50 nM (18S rRNA)
TAMRA probe, and 100 ng (Lrp5/6) or 10 ng (18S rRNA) of total RNA.
The reverse-transcription step was performed at 48 8C for 30 min,
after which PCR was performed at 95 8C for 10 min, followed by 40
cycles of 95 8C for 15 s and 60 8C for 1 min. Standard curves were
performed for each gene to be analyzed, and used to determine the
relative value of mRNA per gene. The value of Lrp5 or Lrp6 mRNA
was normalized to endogenous 18S rRNA and expressed in terms of a
fold-change over the negative control. All samples were run in
triplicate for each reaction, and all experiments were performed and
analyzed a total of three times.
DKK-1 binding assays. Cells were seeded on chambered glass slides
(Lab Tek II; Nalge Nunc International, http://www.nalgenunc.com)
and siRNA transfections were performed on PR230-CHO cells as
described above. After 48 h siRNA treatment, the slides were placed
on ice and the chambers washed with ice-cold culture medium.
Following this, cells were incubated with ice-cold culture medium
supplemented with 100 pM His-tagged DKK-1 (R&D Systems, http://
www.rndsystems.com) or culture medium alone for 2 h. Cells were
then washed three times with ice-cold PBS and ﬁxed with 4%
formalin for 15 min. Cells were rinsed with PBS and blocked for 40
min with 10% FBS in PBS. A FITC-conjugated anti-His antibody
(Invitrogen, 1:1000) was used to detect DKK-1. Cells were then washed
twice with PBS þ 0.1% Triton-X100, mounted, and imaged using a
Zeiss 510 confocal microscope and Zeiss image acquisition software
(http://www.zeiss.com). All images were acquired using identical
parameters.
Supporting Information
Table S1. List and Sequences of Primers Used in This Study
Found at doi:10.1371/journal.ppat.0030027.st001 (61 KB DOC)
Video S1. J774A.1 Macrophages Treated with PA Plus LF
J774A.1 murine macrophages treated with PA plus LF undergo
abrupt lysis and cell death within 4 h of treatment. Images acquired
with the assistance of Art Alberts, Van Andel Research Institute.
Found at doi:10.1371/journal.ppat.0030027.sv001 (1.1 MB MOV)
Accession Number
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html)
accession number for image clone 285207 is N66273.
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